Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

Journal of Clinical Oncology

Volumn 23, Issue 28, 2005, Pages 7178-7187

  Quinn, Jennifer A ^a   Desjardins, Annick ^b   Weingart, Jon ^b   Brem, Henry ^b   Dolan, M Eileen ^b   Delaney, Shannon M ^b   Vredenburgh, James ^b   Rich, Jeremy ^b   Friedman, Allan H ^b   Reardon, David A ^b   Sampson, John H ^b   Pegg, Anthony E ^b   Moschel, Robert C ^b   Birch, Robert ^b   McLendon, Roger E ^b   Provenzale, James M ^b   Gururangan, Sridharan ^b   Dancey, Janet E ^b   Maxwell, Jill ^b   Tourt Uhlig, Sandra ^b   Herndon II, James E ^b   Bigner, Darell D ^b   Friedman, Henry S ^b   more..

^a DUKE CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; GUANINE; O(6) BENZYLGUANINE; O(6)-BENZYLGUANINE;

ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRANIOTOMY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; ADULT; AGED; BRAIN TUMOR; DISEASE COURSE; FEMALE; GLIOMA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DACARBAZINE; DISEASE PROGRESSION; FEMALE; GLIOMA; GUANINE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED;

EID: 27244442921     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.502     Document Type: Article

References (56)

1. Fine HA: The basis for current treatment recommendations for malignant gliomas. J Neurooncol 20:111-120, 1994
2. Levin VA: Chemotherapy of primary brain tumors. Neural Clin 3:855-866, 1985
3. Shapiro WR: Therapy of adult malignant brain tumors: What have the clinical trials taught us? Semin Oncol 13:38-45, 1986
4. Bower M, Newlands ES, Bleehen NM, et al: Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40:484-488, 1997
5. Yung A: Randomised trial of temozolomide vs. procarbazine in glioblastoma multiforme at first relapse. J Neurooncol 39:10-14, 1998
6. Yung WK, Prados MD, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762-2771, 1999
7. Janinis J, Efstathiou E, Panopoulos C, et al: Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status. Med Oncol 17:106-110, 2000
8. Yung WK, Albright RE, Olson J, et al: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593, 2000
9. Brada M, Hoang-Xuan K, Rampling R, et al: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259-266, 2001
10. Brandes AA, Ermani M, Basso U, et al: Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study. Ann Oncol 12:255-257, 2001
11. Khan RB, Raizer JJ, Malkin MG, et al: A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neurooncol 4:39-43, 2002
12. Friedman HS, Dolan ME, Pegg AE, et al: Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 55:2853-2857, 1995
13. Friedman HS, Kokkinakis DM, Pluda J, et al: Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16:3570-3575, 1998
14. Dolan ME, Mitchell RB, Mummert C, et al: Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 51:3367-3372, 1991
15. Wedge SR, Porteous JK, Newlands ES: 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 74:1030-1036, 1996
16. Bocangel DB, Finkelstein S, Schold SC, et al: Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 8:2725-2734, 2002
17. 6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors. Carcinogenesis 5:121-124, 1984
18. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851-3857, 1998
19. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
20. 6- methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 2:735-741, 1996
21. 6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer 73:1049-1052, 1996
22. 6-benzylguanine: A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 59:2402-2410, 1999
23. 6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res 8:2519-2523, 2002
24. 6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neurooncol 6:28-32, 2004
25. 6- benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun 2:371-377, 1990
26. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
27. 6-benzylguanine in humans: Metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol 16:1803-1810, 1998
28. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375-1382, 2002
29. Stupp R, Mason WP, Van Den Bent MJ et al: Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group, American Society of Clinical Oncology 40th Annual Meeting. New Orleans, LA, American Society of Clinical Oncology, 2004, pp 1
30. Prados MD, Yung WK, Fine HA, et al: Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro-oncol 6:33-37, 2004
31. Chang SM, Prados MD, Yung WK, et al: Phase Il study of neoadjuvant 1,3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: A North American Brain Tumor Consortium Trial. Cancer 100:1712-1716, 2004
32. Gibson NW, Hickman JA, Erickson LC: DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2- chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one. Cancer Res 44:1772-1775, 1984
33. 6- methylguanine residues elicit DNA repair synthesis by human cell extracts. J Biol Chem 268:15878-15886, 1993
34. Griffin S, Branch P, Xu YZ, et al: DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: Implications for tolerance to DNA methylation damage. Biochemistry 33:4787-4793, 1994
35. 6- alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg 70:573-577, 1989
36. Belanich M, Pastor M, Randall T, et al: Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56:783-788, 1996
37. 6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 21:135-140, 1994
38. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bischloroethylnitrosourea: A Southwest Oncology Group study. J Clin Oncol 16:3310-3315, 1998
39. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354, 2000
40. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 67:1299-1302, 1993
41. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 32:471-476, 1993
42. 6-benzylguanine: A comparative study in vitro. Br J Cancer 73:482-490, 1996
43. 6-benzylguanine (NSC-637037) and 1,3-bis(2-chloroethyl)-1- nitrosourea (NSC 409962) in mice. American Association for Cancer Res, 1994, pp 1954
44. 6-benzylguanine (NSC637037) and BCNU (carmustine, NSC0409962) in male and female Beagle dogs. American Association for Cancer Res, 1994, pp 1952
45. 6-benzylguanine in mice and dogs. American Association for Cancer Res, 1994, pp 1953
46. 6-alkylguanine-DNA alkyltransferase activity in human myeloid cells. J Clin Invest 76:2106-2114, 1985
47. 6-benzylguanine plus BCNU. Blood 88:1649-1655, 1996
48. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 18:3522-3528, 2000
49. 6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20:2277-2283, 2002
50. 3H)-one (CCRG 81045: M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846-5852, 1987
51. Newlands ES, Blackledge GR, Slack JA, et al: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287-291, 1992
52. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 69:452-156, 1994
53. 6-benzylguanine/temozolomide combination: An evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 40:266-272, 1997
54. Hirose Y, Kreklau EL, Erickson LC, et al: Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg 98:591-598, 2003
55. 6-benzylguanine (O6BG) and temozolomide (TMZ) in pediatric patients with solid tumors, in Bigner DD (ed), Annual Meeting of the Society for Neuro-Oncology. Keystone, CO, Duke University Press, 2003, pp 360
56. Gerson SL: MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296-307, 2004